Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

In vivo and post-mortem studies have demonstrated that increased nigral iron content in patients with Parkinson's disease is a prominent pathophysiological feature. However, the mechanism and risk factors associated with nigral iron deposition in patients with Parkinson's disease have not been identified and represent a key challenge in understanding its pathogenesis and for its diagnosis. In this study, we assessed iron levels in patients with Parkinson's disease and in age- and gender-matched control subjects by measuring phase values using magnetic resonance based susceptibility-weighted phase imaging in a 3T magnetic resonance system. Phase values were measured from brain regions including bilateral substantia nigra, globus pallidus, putamen, caudate, thalamus, red nucleus and frontal white matter of 45 patients with Parkinson's disease with decreased or normal serum ceruloplasmin levels, together with age- and gender-matched control subjects. Correlative analyses between phase values, serum ceruloplasmin levels and disease severity showed that the nigral bilateral average phase values in patients with Parkinson's disease were significantly lower than in control subjects and correlated with disease severity according to the Hoehn and Yahr Scale. The Unified Parkinson's Disease Rating Scale motor scores from the clinically most affected side were significantly correlated with the phase values of the contralateral substantia nigra. Furthermore, nigral bilateral average phase values correlated highly with the level of serum ceruloplasmin. Specifically, in the subset of patients with Parkinson's disease exhibiting reduced levels of serum ceruloplasmin, we found lowered nigral bilateral average phase values, suggesting increased nigral iron content, while those patients with normal levels of serum ceruloplasmin exhibited no changes as compared with control subjects. These findings suggest that decreased levels of serum ceruloplasmin may specifically exacerbate nigral iron deposition in patients with Parkinson's disease. Combining susceptibility-weighted phase imaging with serum ceruloplasmin determination is likely to be useful for the diagnosis and assessment of a subset of patients with Parkinson's disease.

[1]  E. Haacke,et al.  Quantification of punctate iron sources using magnetic resonance phase , 2010, Magnetic resonance in medicine.

[2]  Z. Xiaomin,et al.  Hypoceruloplasminemia‐related movement disorder without Kayser‐Fleischer rings is different from Wilson disease and not involved in ATP7B mutation , 2009, European journal of neurology.

[3]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging: Comparison of field-dependent (FDRI) and phase (SWI) methods , 2009, NeuroImage.

[4]  R. Grossman,et al.  Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging , 2009, Journal of magnetic resonance imaging : JMRI.

[5]  E. Ross,et al.  Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease , 2008, Journal of Neurology.

[6]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[7]  B. Ritz,et al.  Genetics of iron regulation and the possible role of iron in Parkinson's disease , 2008, Neurobiology of Disease.

[8]  Alberto Albertini,et al.  Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.

[9]  Xiaojun Xu,et al.  Age, gender, and hemispheric differences in iron deposition in the human brain: An in vivo MRI study , 2008, NeuroImage.

[10]  Carlo Ciulla,et al.  Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain , 2007, Journal of magnetic resonance imaging : JMRI.

[11]  Daniela Berg,et al.  Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[12]  V. Vassiliev,et al.  Ceruloplasmin in neurodegenerative diseases , 2005, Brain Research Reviews.

[13]  P. Bauer,et al.  Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease , 2004, Neurology.

[14]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[15]  Yu-Chung N. Cheng,et al.  Susceptibility weighted imaging (SWI) , 2004, Zeitschrift fur medizinische Physik.

[16]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[17]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[18]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[19]  J. Snaedal,et al.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. , 1999, Pharmacology & toxicology.

[20]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[21]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[22]  O. Hornykiewicz.  Biochemical aspects of Parkinson's disease , 1998, Neurology.

[23]  J. Cummings,et al.  Alzheimer's disease , 1998, Neurology.

[24]  Y. Wada,et al.  Hereditary ceruloplasmin deficiency with hemosiderosis , 1996, Human Genetics.

[25]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[26]  H. Morita,et al.  Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a japanese family , 1995, Annals of neurology.

[27]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[29]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[30]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[31]  J. Lukens,et al.  Iron metabolism in copper-deficient swine. , 1968, The Journal of clinical investigation.

[32]  S. Osaki.  Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). , 1966, The Journal of biological chemistry.

[33]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[34]  M. Muckenthaler,et al.  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.

[35]  N. Schuff.  Potential role of high‐field MRI for studies in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[36]  E. Haacke,et al.  Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.

[37]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[38]  R. Krüger,et al.  The FASEB Journal express article 10.1096/fj.04-3486fje. Published online September 8, 2005. Functional relevance of ceruloplasmin mutations in Parkinson’s Disease , 2022 .